Sphingosine 1-phosphate receptor 1 agonists: A patent review (2013-2015)

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 4, 2016, Pages 455-470

  Guerrero, Miguel ^a   Urbano, Mariangela ^a   Roberts, Edward ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

autoimmune and inflammatory diseases; bradycardia; FTY720 (fingolimod); lymphopenia; Selective S1P 1 R agonists

Indexed keywords

FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1 AGONIST; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AGONIST; AUTOIMMUNE DISEASE; DRUG ACTIVITY; DRUG APPROVAL; DRUG RESEARCH; HUMAN; INFLAMMATION; NONHUMAN; PATENT; REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; AUTOIMMUNE DISEASES; COMPARATIVE STUDY; DRUG DESIGN; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DESIGN; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATENTS AS TOPIC; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84961199748     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1157165     Document Type: Review

References (87)

1. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov. 2009;8:297-307.
2. Rosen H P J G-C, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem. 2009;78:743-768.
3. Rivera J R L P, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753-763.
4. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407.
5. Clair T, Aoki J, Koh E, et al. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine- 1-phosphate. Cancer Res. 2003;63:5446-5453.
6. Mendoza A, Bréart B, Ramos-Perez WR, et al. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1- phosphate. Cell Rep. 2012;2:1104-1110.
7. Candelore MR, Wright MJ, Tota LM, et al. Phytosphingosine 1- phosphate: a high affinity ligand for the S1P4/Edg-6 receptor. Biochem Biophys Res Commun. 2002;297:600-606.
8. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69-94.
9. Gonzalez-Cabrera PJ, Brown S, Studer SM, et al. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109.
10. Liang J, Nagahashi M, Kim EY, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107-120.
11. Montrose DC, Scherl EJ, Bosworth BP, et al. Hla1 T. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013;54:843-851.
12. Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146:980-991.
13. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883-897.
14. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759-777.
15. Park SI, Felipe CR, Machado PG, et al. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. Braz J Med Biol Res. 2005;38:683-694.
16. Shea BS, Brooks SF, Fontaine BA, et al. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol. 2010;43:662-673.
17. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
18. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.
19. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279:13839-13848.
20. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167:1035-1047.
21. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339-47.
22. Murakami A, Takasugi H, Ohnuma S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol. 2010;77:704-713.
23. 3) in rat. PLoS One. 2012;7:e52985.
24. Urbano M, Guerrero M, Rosen H, et al. Modulators of the Sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett. 2013;23:6377-6389.
25. Hanson MA, Roth CB, Jo E, et al. Crystal structure of a lipid G protein-coupled receptor. Science. 2012;335:851-5.
26. Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives. WO014141171. 2014.
27. Akaal Pharma Pty Ltd. Organic compounds. WO014063199 2014.
28. Allergan Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2- ol Derivatives As Sphingosine-1 Phosphate Receptors Modulators. Wo013036530. 2013.
29. Allergan Inc. Azetidine Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140228341. 2014.
30. Allergan Inc. Sulfinylbenzyl and thiobenzyl derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0130217652. 2013.
31. Allergan Inc. Azetidine derivatives as sphingosine-1 Phosphate receptors modulators. WO015026914. 2014.
32. Allergan Inc. Alkyl Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO015026922. 2015.
33. Allergan Inc. Phenoxy-azetidine Derivatives As Sphingosine-1-phosphate (S1P) Receptor Modulators. US0130217667. 2013.
34. Allergan Inc. Phenoxy-azetidine Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. WO015085153. 2015.
35. Allergan Inc. Phenoxy Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0130217651. 2013.
36. Allergan Inc. Phenoxy Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. WO015085174. 2015.
37. Allergan Inc. Disubstituted Phenoxy Azetidine Derivatives As Sphingosine-1-phosphate (S1P) Receptor Modulators. WO015073547. 2015.
38. Allergan Inc. Disubstituted Phenoxy Derivatives As Sphingosine-1- phosphate (S1P) Receptor Modulators. WO015073556. 2015.
39. Allergan Inc. Alkene Azetidine Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140228344. 2014.
40. Allergan Inc. Alkene Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. WO014124234. 2014.
41. Allergan Inc. Allene Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140135293. 2014.
42. Allergan Inc. Disubstituted Aryl Azetidine Derivatives As Sphingosine- 1-phosphate Receptors Modulators. WO015021109. 2015.
43. Allergan Inc. Disubstituted Aryl Oxy Derivatives As Sphingosine-1- Phosphate Receptors Modulators. WO015021112. 2015.
44. Allergan Inc. Novel Compounds As Receptor Modulators With Therapeutic Utility. US0130157982. 2013.
45. Allergan Inc. Phosphonic Acid Compounds As Sphingosine-1-phosphate Receptor Modulators. US0140256945. 2014.
46. Allergan Inc. Novel Aromatic Thio Compounds As Receptor Modulators. WO014093253. 2014.
47. Allergan Inc. Bicyclic Derivatives As Sphingosine-1 -phosphate Receptors Modulators. WO015163936. 2015.
48. Allergan Inc. Aryl Azetidine Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO015023839. 2015.
49. Allergan Inc. Aryl Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO015023837. 2015.
50. Allergan Inc. Amino Diol Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140221498. 2014.
51. Allergan Inc. Alkyne Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140228445. 2014.
52. Allergan Inc. Aryl Oxadiazole Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. US0140135366. 2014.
53. Allergan Inc. 1, 2, 4-oxadiazoles Azetidine Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO014055921. 2014.
54. Allergan Inc. Substituted Aryl-1,2,4-oxadiazole Derivatives Useful For The Treatment Of Interalia Ocular Or Inflammatory Diseases. WO014055916. 2014.
55. Allergan Inc. Bicyclic 1, 2, 4-oxadiazoles Derivatives As Sphingosine- 1 Phosphate Receptors Modulators. WO014055911. 2014.
56. Allergan Inc. Aromatic Compounds Having Sphingosine-1-phosphonate (S1P) Receptor Activity. US0130018019. 2013.
57. Allergan Inc. Substituted Diaryl Derivatives As Sphingosine Receptor Modulators. US0140235585. 2014.
58. Allergan Inc. Substituted Diaryl Azetidine Derivatives As Sphingosine Receptor Modulators. US0140235613. 2014.
59. Allergan Inc. Substituted Dihydropyrazoles As Sphingosine Receptor Modulators. US0140228324. 2014.
60. Allergan Inc. Substituted Pyrazole Azetidines As Sphingosine Receptor Modulators. US0140228345. 2014.
61. Allergan Inc. Substituted 4,5-dihydropyrazole-1,2,4-oxadiazole Derivatives As Sphingosine Receptor Modulators. Wo014127149. 2014.
62. Allergan Inc. Substituted 1h-pyrazol-1,2,4-oxadiazole Derivatives As Sphingosine Receptor Modulators. Wo014127141. 2014.
63. Allergan Inc. 2-thio-1,3,4-oxadiazoles Azetidine Derivatives As Sphingosine-1 Phosphate Receptors Modulators. US0140135365. 2014.
64. Allergan Inc. 2-thio-1,3,4-oxadiazoles Derivatives As Sphingosine-1 Phosphate Receptors Modulators. US20140135291. 2014.
65. Allergan Inc. Diphenyl Urea Derivatives As Formyl Peptide Receptor Modulators. WO2015108577. 2015.
66. Allergan Inc. 1,3,4-alkenyl Oxadiazole Amino Acid Derivatives As Sphingosine-1-phosphate Receptors'Modulators.WO015073140. 2015.
67. Allergan Inc. 1,3,4-oxadiazoles-2-thio Azetidine Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO2014071355. 2014.
68. Allergan Inc. 1,3,4-oxadiazoles-2-thio Derivatives As Sphingosine-1 Phosphate Receptors Modulators. WO014071342. 2014.
69. Allergan Inc. Pyrazole Azetidine Derivatives As Sphingosine 1-phosphate (s1p) Receptor Modulators. WO014130927. 2014.
70. Allergan Inc. Pyrazole Derivatives As Sphingosine 1-phosphate (S1P) Receptor Modulators. WO014130947. 2014.
71. Allergan Inc. Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides As Sphingosine Receptor Modulators. US0140235592. 2014.
72. Biogen Indec Ma Inc. S1p And/or Atx Modulating Agents. WO014081752. 2014.
73. Biogen Indec Ma Inc. S1p And/or Atx Modulating Agents. WO014081756. 2014.
74. Bristol-Myer Squibb, Bicyclic Compounds. US0140235591. 2014.
75. Institute of Materia Medica, Chinese academy of medical science, Amino-propylene-glycol Derivatives, Preparation Method And Pharmaceutical Composition And Use Thereof. WO013004190. 2013.
76. LG Life Science LTD. Sphingosine-1-phosphate Receptor Agonists, Methods Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent. WO014129796. 2014.
77. Richard D. Cadwell, Heterobicyclic Sphingosine 1-phosphate Analogs. US0140100195. 2014.
78. SANOFI. Carboxylic Acid Derivatives Having An Oxazolo[4,5-c]pyridine Ring. US0130023558. 2013.
79. SANOFI. Carboxylic Acid Derivatives Having An Oxazolo[5,4-b]pyridine Ring. US0130023557. 2013.
80. SANOFI. Cycloalkyloxycarboxylic Acid Derivatives. US0130023545. 2013.
81. SANOFI. Carboxylic Acid Derivatives Having An Oxazolo[5,4-d]pyrimidine Ring. Us0130023544. 2013.
82. Suzhou Connect Biopharmaceuticals, LTD. Immune Adjustment Compound, Use Thereof And Pharmaceutical Composition Comprising Same. WO015039587 2015.
83. The Regents of the University of California Azacyclic Constrained Analogs Of Fty720. WO015009731. 2015
84. West-Faelische Wilhelms-Universitaet Muenster, New Ligands For Targeting Of S1p Receptors For In Vivo Imaging And Treatment Of Diseases. WO013026765. 2013.
85. Briard E, Rudolph B, Desrayaud S, et al. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod). ChemMedChem. 2015;10:1008-1018.
86. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51:817-834.
87. Ghose AK, Herbertz T, Hudkins RL, et al. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery. ACS Chem Neurosci. 2012;3:50-68